TWO drug executives walked into a bar. No, this is not the start of a joke. The workers for Roche, a Swiss drugs firm, had been dining with doctors after a medical conference. At the bar, alleged an anonymous complaint in a recent report by a British industry watchdog, they bought the doctors drinks (“shots of varying colours flowed like hot lava”). One executive danced on stage, prompting bar staff to throw him out. Roche maintains its managers ran into the doctors and did not buy them drinks. But the evening hardly seems like the finest moment in the history of ties between doctors and drug companies.
两名制药公司的高管走进一家酒吧。别理解错了,这可不是在讲笑话。瑞士制药企业罗氏公司(Roche)的员工开完医学会议后,此时正和医生们共进晚餐。在一家英国行业监督机构最近发表的报告中,一位匿名人士指控这两名员工在酒吧请医生喝酒(“照片上的酒颜色各异,像喷涌而出的火热岩浆”)。一名高管登台起舞,结果被酒吧服务人员赶了出去。瑞士公司则坚持认为,其负责人是偶然碰到几位医生的,而且也没有请他们喝酒。但这个夜晚怎么看也不像是医生与制药企业的关系史上最美好的时刻。
That relationship is a poorly regulated muddle. At one (beneficial) extreme, firms work with doctors to create new treatments. At the other end of the spectrum, firms bribe doctors to prescribe their drugs. America’s justice department has wrung huge settlements from companies over such charges. Between these poles is a lot of activity deemed standard by some, repugnant by others—and which is increasingly subject to new laws.
【揭露药医利益关系的新招】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15